Zenosense, Inc. — MIDS Hybrid Strip Detection Testing to Commence

Press release Jul 05, 2017 OTC Disclosure & News Service Zenosense, Inc. — MIDS Hybrid Strip Detection Testing to Commence VALENCIA, SPAIN–(Marketwired – Jul 5, 2017) – Zenosense, Inc. (OTC PINK: ZENO) (“Zenosense”, the “Company”), a healthcare technology company primarily focused on the development and commercialization of MIDS Cardiac™, a Point of Care (“POC”) handheld…

Details

Zenosense, Inc.: MIDS Medical Engages Future Diagnostics for Assay Consulting Services

Press release Mar 28, 2017 OTC Disclosure & News Service Zenosense, Inc.: MIDS Medical Engages Future Diagnostics for Assay Consulting Services VALENCIA, SPAIN–(Marketwired – Mar 28, 2017) – Zenosense, Inc. (OTCQB: ZENO) (“Zenosense”, the “Company”), a healthcare technology company primarily focused on the development and commercialization of MIDS Cardiac™, a Point of Care (“POC”) handheld…

Details

Zenosense, Inc.: MIDS Quantitative Testing Results

Press release Mar 10, 2017 OTC Disclosure & News Service Zenosense, Inc.: MIDS Quantitative Testing Results VALENCIA, SPAIN–(Marketwired – Mar 10, 2017) – Zenosense, Inc. (OTCQB: ZENO) (“Zenosense,” the “Company”), a healthcare technology company primarily focused on the development and commercialization of MIDS Cardiac™, a Point of Care (“POC”) handheld device for the early detection…

Details

Zenosense, Inc.: MIDS Quantitative Testing Commences

Press release Feb 22, 2017 OTC Disclosure & News Service Zenosense, Inc.: MIDS Quantitative Testing Commences VALENCIA, SPAIN–(Marketwired – Feb 22, 2017) – Zenosense, Inc. (OTCQB: ZENO) (“Zenosense”, the “Company”), a healthcare technology company primarily focused on the development and commercialization of MIDS Cardiac™, a Point of Care (“POC”) handheld device for the early detection…

Details

Zenosense, Inc.: New Patent Application for Additional MIDS Detection Method

Press release Jan 23, 2017 OTC Disclosure & News Service Zenosense, Inc.: New Patent Application for Additional MIDS Detection Method VALENCIA, SPAIN–(Marketwired – Jan 23, 2017) – Zenosense, Inc. (OTCQB: ZENO) (“Zenosense”, the “Company”), a healthcare technology company primarily focused on the development and commercialization of MIDS Cardiac™, a Point of Care (“POC”) handheld device…

Details

Zenosense, Inc. MIDS Proof of Market Report

Press Release Nov 17, 2016 OTC Disclosure & News Service Zenosense, Inc. MIDS Proof of Market Report VALENCIA, SPAIN–(Marketwired – Nov 17, 2016) – Zenosense, Inc. (OTCQB: ZENO) (“Zenosense”, the “Company”), a healthcare technology company primarily focused on the development and commercialization of MIDS Cardiac™, a Point of Care (“POC”) handheld device for the early…

Details

Zenosense, Inc. MIDS Cardiac Bench Reader Development

Press Release VALENCIA, SPAIN–(Marketwired – Oct 31, 2016) –  Zenosense, Inc. (OTCQB: ZENO) (“Zenosense”, the “Company”), a healthcare technology company primarily focused on the development and commercialization of MIDS Cardiac™, a Point of Care (“POC”) handheld device for the early detection of certain cardiac event biomarkers to significantly accelerate the triage, diagnosis, treatment and disposition…

Details

Zenosense, Inc. General Update – Cardiac Device Development

VALENCIA, SPAIN–(Marketwired – Sep 19, 2016) –  Zenosense, Inc. ( OTC PINK : ZENO ) (“Zenosense”, the “Company”), a healthcare technology company primarily focused on the development and commercialisation of MIDS Cardiac™, a Point of Care (“POC”) hand held device for the early detection of certain cardiac event biomarkers to significantly accelerate the triage, diagnosis,…

Details

Zenosense, Inc. – Hospital Collaboration – 400 Person Lung Cancer Detection Trial

VALENCIA, SPAIN–(Marketwired – Dec 17, 2014) – Zenosense, Inc. ( OTCQB : ZENO ) (“Zenosense”, the “Company”), a healthcare technology company primarily focused on developing and marketing devices to detect the MRSA “Super-Bug” and to detect signs of lung cancer in exhaled breath, is pleased to announce that on 16 December 2014, the Company’s development…

Details

Zenosense, Inc. Reports Manufacturing of Pre-Commercial Lung Cancer Detection Device

VALENCIA, SPAIN–(Marketwired – Nov 4, 2014) – Zenosense, Inc. ( OTCQB : ZENO ) (“Zenosense,” the “Company”), a healthcare technology company primarily focused on developing and marketing devices to detect the MRSA “Super-Bug” and to detect signs of lung cancer in exhaled breath, is pleased to announce the manufacturing of a pre-commercial prototype device to…

Details